https://www.avient.com/knowledge-base/article/top-five-ways-enhance-ergonomics-healthcare-products
They require devices and equipment tailored for physical limitations caused by conditions ranging from arthritis to chronic obstructive pulmonary disease (COPD) to osteoporosis.
Orthotics: Foot orthotics may be prescribed for medical conditions affecting the elderly, such as diabetes, peripheral vascular disease and degenerative joint and skin problems.
Prosthetics: Elderly people may experience loss of a limb due to conditions such as diabetes, peripheral vascular disease or skin cancer.
https://www.avient.com/investor-center/news/polyone-raises-outlook-fourth-quarter-2019-adjusted-earnings
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
color and additive masterbatch business; the satisfaction or waiver of conditions in the purchase agreements; any material adverse changes in
Pro Forma for sale of PP&S.
https://www.avient.com/investor-center/news/polyone-announces-fourth-quarter-and-full-year-2019-results
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
Short-term and current portion of long-term debt
Long-term debt
https://www.avient.com/investor-center/news/avient-announces-pricing-725-million-7125-senior-notes-due-2030
subject to customary closing conditions.
intends to use the net proceeds from the offering, along with borrowings under a new term loan and cash on hand, to finance its pending acquisition from Koninklijke DSM N.V.
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
https://www.avient.com/investor-center/news/polyone-announces-full-year-and-fourth-quarter-2018-results
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
Short-term and current portion of long-term debt
Long-term debt
https://www.avient.com/investor-center/news/polyone-signs-agreement-divest-designed-structures-and-solutions
The sale of DSS is subject to satisfaction of regulatory requirements and other customary closing conditions, which the company expects to be completed in the third quarter of 2017.
Proceeds from the sale will be used to pay down short term borrowings and fund ongoing growth initiatives.
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
https://www.avient.com/investor-center/news/polyone-host-investor-conference-call
As such, and given recent inbound investor inquiries regarding current market conditions and the Clariant transaction, we are going to host this call Friday to discuss these topics.
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
the time required to consummate the acquisition of Clariant's color and additive masterbatch business; the satisfaction or waiver of conditions in the purchase agreements; any material adverse changes in Clariant's color and additive masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the proposed acquisition of Clariant's color and additive masterbatch business; our ability to achieve the strategic and other objectives relating to the proposed acquisition of Clariant's color and additive masterbatch business, including any expected synergies; our ability to successfully integrate Clariant's color and additive masterbatch business and achieve the expected results of the acquisition of Clariant's color and additive masterbatch business, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to raise or sustain prices for products or services; an ability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to acquisitions and integration, working capital reductions, costs reductions and employee productivity goals; information systems failures and cyberattacks; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.
https://www.avient.com/investor-center/news/avient-announces-commencement-725-million-senior-notes-offering
The closing of the offering is expected to occur prior to, and is not conditioned upon, the consummation of the Acquisition.
This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
https://www.avient.com/investor-center/news/avient-announces-debt-paydown-and-term-loan-refinancing
of the existing term loans, bringing the outstanding principal to
Under the amendment, the term loan bears interest at the sum of Adjusted Term SOFR plus 2.50% or the sum of the Base Rate plus 1.50%.
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
https://www.avient.com/investor-center/news/polyone-announces-leadership-appointments
She has led strategic insights and market research, re-invigorated the company's Inside Sales function, and launched a focus on the customer experience that will continue to differentiate
They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales.
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: the time required to consummate the acquisition of Clariant's masterbatch business; the satisfaction or waiver of conditions in the Clariant masterbatch purchase agreements; any material adverse changes in Clariant's masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the acquisition of Clariant's masterbatch business; our ability to achieve the strategic and other objectives relating to the acquisition of Clariant's masterbatch business, including any expected synergies; and our ability to successfully integrate Clariant's masterbatch business and achieve the expected results of the acquisitions, including, without limitation, the acquisitions being accretive.